Daratumumab-based treatment for immunoglobulin light-chain amyloidosis

Keyphrases

• Daratumumab 100%
• Immunoglobulin Light Chain Amyloidosis 100%
• Hematologic 50%
• Complete Response 25%
• Major Organs 25%
• Confidence Interval 16%
• CD38 16%
• Cyclophosphamide 16%
• Newly Diagnosed 16%
• Bortezomib 16%
• AL Amyloidosis 16%
• Plasma Cells 8%
• Pneumonia 8%
• Hazard Ratio 8%
• Adverse Events 8%
• Cardiomyopathy 8%
• Diarrhea 8%
• Systemic Administration 8%
• Improved Outcomes 8%
• Amyloid Fibrils 8%
• Amyloidosis 8%
• Light Chain Amyloidosis 8%
• Cardiac Failure 8%
• Renal Response 8%
• Cardiac Response 8%
• Light Chain 8%
• Lymphopenia 8%
• Immunoglobulin Light Chains 8%
• Targeting Antibodies 8%
• Relative Risk Ratio 8%

Immunology and Microbiology

• Daratumumab 100%
• AL Amyloidosis 100%
• Dexamethasone 16%
• Cyclophosphamide 16%
• CD38 16%
• Lymphocytopenia 8%
• Light Chain 8%
• Amyloidosis 8%
• Fibril 8%
• Immunoglobulin Light Chain 8%
• Immunoglobulin Producing Cell 8%
• Immunology 8%